Tumour budding and CD8
CD8
digital image analysis
neoadjuvant therapy
rectal cancer
tumour budding
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
07
10
2020
accepted:
17
12
2020
pubmed:
20
12
2020
medline:
24
11
2021
entrez:
19
12
2020
Statut:
ppublish
Résumé
Tumour budding ('attacker') and CD8 Using digital scans of all tumour slides/case, we analysed CD8 In rectal cancer, tumour budding has clinical relevance in both primarily surgically treated patients and in those with neoadjuvantly treated patients, where it characterises highly aggressive residual disease. CD8
Substances chimiques
CD8 Antigens
0
Keratins
68238-35-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1009-1018Subventions
Organisme : KWF Kankerbestrijding
ID : 10602
Organisme : KWF Kankerbestrijding
ID : 2016-2
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Lugli A, Kirsch R, Ajioka Y et al. Recommendations for reporting tumor budding in colorectal cancer based on the international Tumor Budding Consensus Conference (ITBCC) 2016. Mod. Pathol. 2017; 30; 1299-1311.
Giger OT, Comtesse SC, Lugli A, Zlobec I, Kurrer MO. Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod. Pathol. 2012; 25; 1048-1053.
Huang Y, Lou XY, Zhu YX et al. Local environment in biopsy better predict the pathological response to neoadjuvant chemoradiotherapy in rectal cancer. Biosci. Rep. 2019; 39; 1-10.
Huebner M, Wolff BG, Smyrk TC, Aakre J, Larson DW. Partial pathologic response and nodal status as most significant prognostic factors for advanced rectal cancer treated with preoperative chemoradiotherapy. World J. Surg. 2012; 36; 675-683.
Rogers AC, Gibbons D, Hanly AM et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod. Pathol. 2014; 27; 156-162.
Dawson H, Christe L, Eichmann M et al. Tumour budding/T cell infiltrates in colorectal cancer: proposal of a novel combined score. Histopathology 2020; 76; 572-580.
Zlobec I, Minoo P, Terracciano L, Baker K, Lugli A. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology 2011; 59; 482-495.
Nearchou IP, Lillard K, Gavriel CG, Ueno H, Harrison DJ, Caie PD. Automated analysis of lymphocytic infiltration, tumor budding, and their spatial relationship improves prognostic accuracy in colorectal cancer. Cancer Immunol. Res. 2019; 7; 609-620.
Boxberg M, Leising L, Steiger K et al. Composition and clinical impact of the immunologic tumor microenvironment in oral squamous cell carcinoma. J. Immunol. 2019; 202; 278-291.
Wartenberg M, Cibin S, Zlobec I et al. Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance. Clin. Cancer Res. 2018; 24; 4444-4454.
Gujam FJ, McMillan DC, Mohammed ZM, Edwards J, Going JJ. The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. Br. J. Cancer 2015; 113; 1066-1074.
Shinto E, Omata J, Sikina A et al. Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer. BJS Open 2020; 4; 301-309.
Du C, Xue W, Li J, Cai Y, Gu J. Morphology and prognostic value of tumor budding in rectal cancer after neoadjuvant radiotherapy. Hum. Pathol. 2012; 43; 1061-1067.
Jesinghaus M, Boxberg M, Wilhelm D et al. Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinoma. Br. J. Cancer 2019; 121; 1050-1057.
Jesinghaus M, Steiger K, Stogbauer F et al. Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma. Br. J. Cancer 2020; 122; 835-846.
World Health Organisation (WHO). Digestive system tumours. In WHO Classification of Tumours Editorial Board eds. WHO Classification of Tumours. 5th ed. Geneva, Switzerland: WHO, 2019; 157-192.
Bankhead P, Loughrey MB, Fernandez JA et al. Qupath: Open source software for digital pathology image analysis. Sci. Rep. 2017; 7; 16878.
Nagtegaal ID, Glynne-Jones R. How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement. Cancer Treat. Rev. 2020; 84; 101964.
Ji D, Yi H, Zhang D et al. Somatic mutations and immune alternation in rectal cancer following neoadjuvant chemoradiotherapy. Cancer Immunol. Res. 2018; 6; 1401-1416.
Chen TW, Huang KC, Chiang SF, Chen WT, Ke TW, Chao KSC. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILS in rectal cancer patients before and after neoadjuvant chemoradiotherapy. J. Cancer Res. Clin. Oncol. 2019; 145; 1043-1053.
Lim YJ, Koh J, Kim S et al. Chemoradiation-induced alteration of programmed death-ligand 1 and CD8(+) tumor-infiltrating lymphocytes identified patients with poor prognosis in rectal cancer: a matched comparison analysis. Int. J. Radiat. Oncol. Biol. Phys. 2017; 99; 1216-1224.
Tsuchiya T, Someya M, Takada Y et al. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. Strahlenther. Onkol. 2020; 196; 725.
Meyer SN, Galvan JA, Zahnd S et al. Co-expression of cytokeratin and vimentin in colorectal cancer highlights a subset of tumor buds and an atypical cancer-associated stroma. Hum. Pathol. 2019; 87; 18-27.
Pages F, Mlecnik B, Marliot F et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018; 391; 2128-2139.
Eriksen AC, Andersen JB, Lindebjerg J et al. Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer? Diagn. Pathol. 2018; 13; 20.